Hello, everyone, and nice to see you again after what was an extended holiday break for some of us on this side of the pond. We hope those of you who were able to indulge enjoyed a refreshing respite, because a serious game of catch-up is now underway. This calls, of course, for a cup or three of stimulation. Our chosen flavor this morning is apple cider donut, for those keeping track. Meanwhile, here are some tidbits to get you started. Have a smashing day and do stay in touch …
Pfizer (PFE) may sell its consumer health care business. The drug maker says it is reviewing “strategic alternatives” that may include a full or partial separation through a spinoff, sale, or some other transaction. Of course, Pfizer may decide to keep the business, which generated $3.4 billion in sales last year, or about 6 percent of total revenue. The unit sells such well-known brands as Advil, Nexium, Robitussin, and Chapstick.
Since the chain pharmacies are losing market share of OTC drugs to online sales, and since Amazon plans to get into selling Rx drugs, the purchase of Pfizer’s consumer products by Amazon would be a good 1-2 punch for their business.
That is a keen insight pharmavet1 – not that you need me to say so.
Comments are closed.